Difference between revisions of "Bacillus Calmette-Guérin (BCG, TheraCys)"
(delete regimen section) |
|||
Line 1: | Line 1: | ||
− | |||
==General information== | ==General information== | ||
Class/mechanism: Live mycobacteria which promote a local acute inflammatory and sub-acute granulomatous reaction with macrophage and leukocyte infiltration in the urothelium and lamina propria of the urinary bladder. This results in a likely T-lymphocyte dependent anti-tumor effect.<ref name="insert">[https://www.vaccineshoppecanada.com/secure/pdfs/ca/immucyst_e.pdf Bacillus Calmette-Guerin (BCG) package insert]</ref><ref>[http://hemonc.org/docs/packageinsert/bacilluscalmetteguerin.pdf Bacillus Calmette-Guerin (BCG) package insert (locally hosted backup)]</ref> | Class/mechanism: Live mycobacteria which promote a local acute inflammatory and sub-acute granulomatous reaction with macrophage and leukocyte infiltration in the urothelium and lamina propria of the urinary bladder. This results in a likely T-lymphocyte dependent anti-tumor effect.<ref name="insert">[https://www.vaccineshoppecanada.com/secure/pdfs/ca/immucyst_e.pdf Bacillus Calmette-Guerin (BCG) package insert]</ref><ref>[http://hemonc.org/docs/packageinsert/bacilluscalmetteguerin.pdf Bacillus Calmette-Guerin (BCG) package insert (locally hosted backup)]</ref> | ||
Line 10: | Line 9: | ||
*[http://chemocare.com/bio/bcg.asp Bacillus Calmette-Guerin (BCG, TheraCys) patient drug information (Chemocare)]<ref>[http://chemocare.com/bio/bcg.asp Bacillus Calmette-Guerin (BCG, TheraCys) patient information (Chemocare)]</ref> | *[http://chemocare.com/bio/bcg.asp Bacillus Calmette-Guerin (BCG, TheraCys) patient drug information (Chemocare)]<ref>[http://chemocare.com/bio/bcg.asp Bacillus Calmette-Guerin (BCG, TheraCys) patient information (Chemocare)]</ref> | ||
*[http://www.uptodate.com/contents/patient-information-bladder-cancer-treatment-non-muscle-invasive-superficial-cancer Patient information about bladder cancer treatment, including BCG (UpToDate)]<ref>[http://www.uptodate.com/contents/patient-information-bladder-cancer-treatment-non-muscle-invasive-superficial-cancer Patient information about bladder cancer treatment, including BCG (UpToDate)]</ref> | *[http://www.uptodate.com/contents/patient-information-bladder-cancer-treatment-non-muscle-invasive-superficial-cancer Patient information about bladder cancer treatment, including BCG (UpToDate)]<ref>[http://www.uptodate.com/contents/patient-information-bladder-cancer-treatment-non-muscle-invasive-superficial-cancer Patient information about bladder cancer treatment, including BCG (UpToDate)]</ref> | ||
− | |||
− | |||
− | |||
− | |||
==References== | ==References== | ||
<references/> | <references/> |
Revision as of 02:51, 24 December 2011
General information
Class/mechanism: Live mycobacteria which promote a local acute inflammatory and sub-acute granulomatous reaction with macrophage and leukocyte infiltration in the urothelium and lamina propria of the urinary bladder. This results in a likely T-lymphocyte dependent anti-tumor effect.[1][2]
Route: Intravesicular
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the package insert[1].
Patient drug information
- Bacillus Calmette-Guerin (BCG, TheraCys) patient drug information (Chemocare)[3]
- Patient information about bladder cancer treatment, including BCG (UpToDate)[4]